IBDEI0WA ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,15689,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15689,1,4,0)
 ;;=4^180.9
 ;;^UTILITY(U,$J,358.3,15689,1,5,0)
 ;;=5^Ca Cervix
 ;;^UTILITY(U,$J,358.3,15689,2)
 ;;=^267214
 ;;^UTILITY(U,$J,358.3,15690,0)
 ;;=203.02^^81^946^104
 ;;^UTILITY(U,$J,358.3,15690,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15690,1,4,0)
 ;;=4^203.02
 ;;^UTILITY(U,$J,358.3,15690,1,5,0)
 ;;=5^Multiple Myeloma,In Relapse
 ;;^UTILITY(U,$J,358.3,15690,2)
 ;;=^336462
 ;;^UTILITY(U,$J,358.3,15691,0)
 ;;=204.02^^81^946^2
 ;;^UTILITY(U,$J,358.3,15691,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15691,1,4,0)
 ;;=4^204.02
 ;;^UTILITY(U,$J,358.3,15691,1,5,0)
 ;;=5^ALL,In Relapse
 ;;^UTILITY(U,$J,358.3,15691,2)
 ;;=^336465
 ;;^UTILITY(U,$J,358.3,15692,0)
 ;;=204.12^^81^946^17
 ;;^UTILITY(U,$J,358.3,15692,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15692,1,4,0)
 ;;=4^204.12
 ;;^UTILITY(U,$J,358.3,15692,1,5,0)
 ;;=5^CLL,In Relapse
 ;;^UTILITY(U,$J,358.3,15692,2)
 ;;=^336466
 ;;^UTILITY(U,$J,358.3,15693,0)
 ;;=204.20^^81^946^114
 ;;^UTILITY(U,$J,358.3,15693,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15693,1,4,0)
 ;;=4^204.20
 ;;^UTILITY(U,$J,358.3,15693,1,5,0)
 ;;=5^Subacute LL w/o Remission
 ;;^UTILITY(U,$J,358.3,15693,2)
 ;;=^336852
 ;;^UTILITY(U,$J,358.3,15694,0)
 ;;=204.21^^81^946^116
 ;;^UTILITY(U,$J,358.3,15694,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15694,1,4,0)
 ;;=4^204.21
 ;;^UTILITY(U,$J,358.3,15694,1,5,0)
 ;;=5^Subacute LL,In Remission
 ;;^UTILITY(U,$J,358.3,15694,2)
 ;;=^267526
 ;;^UTILITY(U,$J,358.3,15695,0)
 ;;=204.22^^81^946^115
 ;;^UTILITY(U,$J,358.3,15695,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15695,1,4,0)
 ;;=4^204.22
 ;;^UTILITY(U,$J,358.3,15695,1,5,0)
 ;;=5^Subacute LL,In Relapse
 ;;^UTILITY(U,$J,358.3,15695,2)
 ;;=^336467
 ;;^UTILITY(U,$J,358.3,15696,0)
 ;;=205.02^^81^946^5
 ;;^UTILITY(U,$J,358.3,15696,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15696,1,4,0)
 ;;=4^205.02
 ;;^UTILITY(U,$J,358.3,15696,1,5,0)
 ;;=5^AML,In Relapse
 ;;^UTILITY(U,$J,358.3,15696,2)
 ;;=^336470
 ;;^UTILITY(U,$J,358.3,15697,0)
 ;;=205.12^^81^946^20
 ;;^UTILITY(U,$J,358.3,15697,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15697,1,4,0)
 ;;=4^205.12
 ;;^UTILITY(U,$J,358.3,15697,1,5,0)
 ;;=5^CML,In Relapse
 ;;^UTILITY(U,$J,358.3,15697,2)
 ;;=^336471
 ;;^UTILITY(U,$J,358.3,15698,0)
 ;;=284.81^^81^946^14
 ;;^UTILITY(U,$J,358.3,15698,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15698,1,4,0)
 ;;=4^284.81
 ;;^UTILITY(U,$J,358.3,15698,1,5,0)
 ;;=5^Aplastic Anemia d/t Drugs
 ;;^UTILITY(U,$J,358.3,15698,2)
 ;;=^335245
 ;;^UTILITY(U,$J,358.3,15699,0)
 ;;=284.89^^81^946^13
 ;;^UTILITY(U,$J,358.3,15699,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15699,1,4,0)
 ;;=4^284.89
 ;;^UTILITY(U,$J,358.3,15699,1,5,0)
 ;;=5^Aplastic Anemia d/t Chronic Disease
 ;;^UTILITY(U,$J,358.3,15699,2)
 ;;=^87880
 ;;^UTILITY(U,$J,358.3,15700,0)
 ;;=289.84^^81^946^119
 ;;^UTILITY(U,$J,358.3,15700,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15700,1,4,0)
 ;;=4^289.84
 ;;^UTILITY(U,$J,358.3,15700,1,5,0)
 ;;=5^Thrombocytopenia,Heparin Induced
 ;;^UTILITY(U,$J,358.3,15700,2)
 ;;=^336542
 ;;^UTILITY(U,$J,358.3,15701,0)
 ;;=V10.91^^81^946^67
 ;;^UTILITY(U,$J,358.3,15701,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15701,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,15701,1,5,0)
 ;;=5^H/O Neuroendocrine CA Tumor
 ;;^UTILITY(U,$J,358.3,15701,2)
 ;;=^338494
 ;;^UTILITY(U,$J,358.3,15702,0)
 ;;=V10.91^^81^946^66
 ;;^UTILITY(U,$J,358.3,15702,1,0)
 ;;=^358.31IA^5^2
 ;;^UTILITY(U,$J,358.3,15702,1,4,0)
 ;;=4^V10.91
 ;;^UTILITY(U,$J,358.3,15702,1,5,0)
 ;;=5^H/O Malignant Neoplasm,Unspec
 ;;
 ;;$END ROU IBDEI0WA
